NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC

Slides:



Advertisements
Similar presentations
M ANAGING ARV REGIMEN FAILURE IN THE HIV INFECTED CHILD Dr L Keet Centre of Excellence HIV Directorate.
Advertisements

New Antiretrovirals for the Treatment of HIV. Convenience, tolerability, simplicity New & Investigational Agents.
TMC278 Update, 30th January 2009  C204 data  ECHO and THRIVE - Phase III studies  New TMC278 formulations Peter Williams Tibotec BVBA, Mechelen, Belgium.
Initiating Antiretroviral Therapy in Treatment-Naive Patients Charles B. Hicks, MD Associate Professor of Medicine, Division of Infectious Diseases and.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Crafting an ART Regimen for Initiation or Salvage: Are NRTI’s Necessary? Brian R. Wood, MD Assistant.
+ Antiretroviral Agents: HIV & AIDS Shaw Vonder Hoya.
HIV Lifecycle and Mechanisms of Antiretroviral Therapy
Dr Emmanuel Nsutebu Consultant Infectious Diseases Physician Tropical and Infectious Diseases Unit Royal Liverpool Hospital HIV “Myths, controversies and.
Salvage Antiretroviral Therapy Guiding Principles, Strategies and the Role of Resistance Testing.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER 2014 IAS-USA Treatment Guidelines Brian R. Wood, MD Medical Director, NW AETC ECHO Assistant Professor.
DHS/HIV/PP HIV/AIDS 2007 Update David H. Spach, MD Clinical Director Northwest AIDS Education and Training Center Professor of Medicine Division of Infectious.
ANTIRETROVIRAL RESISTANCE Jennifer Fulcher, MD, PhD.
Failure Therapy VIRAL RESITANCE ADHERENCE!!!!!!!!!!! DRUG INTERACTION.
1 Review of Antiretroviral Therapy in Adults HAIVN Harvard Medical School AIDS Initiative in Vietnam.
Case 1: 23-year-old Male Student Clinical Director, Division of Infectious Diseases Brigham and Women’s Hospital Professor of Medicine Harvard Medical.
© IAS–USA Johnson VA et al. Top Antivir Med. 2011;19(4): Updates, user notes, and references available at Mutations in the.
Predicting NNRTI Resistance – do polymorphisms matter? Nicola E Mackie 1, Lucy Garvey 1, Anna Maria Geretti 2, Linda Harrison 3, Peter Tilston 4, Andrew.
Increased phenotypic susceptibility (hypersusceptibility, HS) to NNRTIs is observed in ~30% of viral isolates with NRTI- resistance mutations 1 and has.
1 Introduction to ARV Therapy HAIVN Harvard Medical School AIDS Initiative in Vietnam.
HIV Principles in Primary Care and Triage of the HIV patient David Aymond, MD, AAHIVM.
Connection Domain Mutations in Treatment-Experienced Patients in the OPTIMA (Options in Management with Antiretrovirals) Trial Birgitt Dau, M.D. Postdoctoral.
Comparison of NNRTI vs NNRTI  ENCORE  EFV vs RPV –ECHO-THRIVE –STAR  EFV vs ETR –SENSE.
Combined PI and NNRTI Resistance Analysis of the Pooled DUET Trial: Towards a Regimen-Based Resistance Interpretation J. M. Schapiro, J. Vingerhoets, S.
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,
Comparison of NNRTI vs PI/r  EFV vs LPV/r vs EFV + LPV/r –A5142 –Mexican Study  NVP vs ATV/r –ARTEN  EFV vs ATV/r –A5202.
Long Term Therapeutic Success of Etravirine in Switch and Naive Patients L.Bull, M.Bower, M.Nelson Chelsea and Westminster Hospital, London.
HIV: WHAT IS NEW? DR NYA EBAMA, M.D. LOWCOUNTRY INFECTIOUS DISEASES, PA CARETEAM PLUS, INC SEPTEMBER 18, 2015.
Management of NRTI Resistance
Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects
Comparison of NNRTI vs NNRTI  ENCORE  EFV vs RPV –ECHO-THRIVE –STAR  EFV vs ETR –SENSE.
N ORTHWEST A IDS E DUCATION AND T RAINING C ENTER Major Changes to the HHS Adult and Adolescent HIV Treatment Guidelines: April 2015 Brian R. Wood, MD.
© IAS–USA Johnson VA et al. Top Antivir Med. 2013;21(1):4-12. Updates, user notes, and references available at Mutations in the Reverse.
Virology – Antivirals 2 JU- 2 nd Year Medical Students By Dr Hamed AlZoubi – Microbiology and Immunology Department – Mutah University. MBBS (J.U.S.T)
POWER 3 Study Confirms Safety and Efficacy of Darunavir/Ritonavir in Treatment-Experienced Patients Slideset on: Molina JM, Cohen C, Katlama C, et al.
ACTG 5142: First-line Antiretroviral Therapy With Efavirenz Plus NRTIs Has Greater Antiretroviral Activity Than Lopinavir/Ritonavir Plus NRTIs Slideset.
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
HIV Drug Resistance Surveillance Satellite Session: HIV Drug Resistance Surveillance and Control: a Global Concern Silvia Bertagnolio, MD WHO,
Phase 3 Treatment-Naïve and Treatment-Experienced
Med Chem Tutoring January 25
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
EFV versus ATV + RTV, both with ABC-3TC or TDF-FTC ACTG 5202
Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.
Figure 1 Inclusion criteria, exclusion criteria, and criteria for virologic failure. CDC, Centers for Disease Control and Prevention; ddC, zalcitabine;
Etravirine in Treatment Experienced DUET-2 (TMC125-C216)
Switch to RPV-TDF-FTC from Ritonavir-boosted PI Regimen SPIRIT STUDY
Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort.
Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227
David van de Vijver PharmD PhD Eijkman-Winkler Institute
Introduction Results Objectives Methods Conclusion Funding
From: Atazanavir Plus Ritonavir or Efavirenz as Part of a 3-Drug Regimen for Initial Treatment of HIV-1A Randomized Trial Ann Intern Med. 2011;154(7):
Once Daily Etravirine versus Efavirenz in Treatment-Naive SENSE Trial
Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study
Etravirine in Treatment Experienced DUET-1 (TMC125-C206)
Darunavir/r versus Other PIs in Treatment Experienced POWER 1 and 2
Saquinavir + RTV versus Lopinavir-RTV in Treatment-Naïve GEMINI Trial
Switching to TDF-FTC from ABC-3TC for Hyperlipidemia ROCKET II
Clinical and virologic follow-up in perinatally HIV-1-infected children and adolescents in Madrid with triple-class antiretroviral drug-resistant viruses 
Comparison of NNRTI vs NNRTI
Drug-resistant human immunodefiency virus
Phase 3 Treatment Naïve and Treatment Experienced HIV Coinfection
Long-Term Clinical and Immunologic Outcomes Are Similar in HIV-Infected Persons Randomized to NNRTI versus PI versus NNRTI+PI-based Antiretroviral Regimens.
Mutations in the Reverse Transcriptase Gene Associated With Resistance to Reverse Transcriptase Inhibitors Nucleoside and Nucleotide Analogue Reverse Transcriptase.
Impact of Baseline NNRTI Mutations on the Virologic Response to TMC125 in the Phase III Clinical Trials DUET-1 and DUET-2 J Vingerhoets, A Buelens, M.
A prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection – ACTG 5142 Riddler S.A.,
Comparison of NRTI combinations
Comparison of NRTI combinations
Comparison of NNRTI vs NNRTI
Differential Detection of M184V/I Between Plasma Historical HIV Genotypes and Proviral DNA from PBMCs N Margot, R Ram, IR McNicholl, R Haubrich, C Callebaut.
Tertiary structures of HIV-1 reverse transcriptase and chemical formulas of NRTIs and NNRTIs. (A) HIV-1 RT complexed with dsDNA and zidovudine triphosphate.
ANTIRETROVIRAL RESISTANCE IN CLINICAL PRACTICE
Presentation transcript:

NNRTI Resistance David H. Spach, MD Principal Investigator, NW AETC Professor of Medicine, Division of Infectious Diseases University of Washington Last Updated: February 23, 2015

NNRTI Mechanisms of Action Resistance to Non-Nucleoside Reverse Transcriptase Inhibitors NNRTI Mechanisms of Action

HIV Reverse Transcription Conversion of HIV RNA to HIV DNA Reverse Transcriptase HIV DNA

HIV Reverse Transcriptase Polymerase Active Site p51 Reverse Transcriptase

HIV Reverse Transcriptase Thumb Fingers Palm p66 Polymerase Active Site p51 Reverse Transcriptase

HIV Reverse Transcription HIV DNA Polymerase Active Site HIV RNA Reverse Transcriptase

Polymerase Active Site Reverse Transcriptase Inhibition of HIV Reverse Transcription Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Polymerase Active Site NNRTI Binding Pocket Reverse Transcriptase

Polymerase Active Site Reverse Transcriptase Inhibition of HIV Reverse Transcription Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) NNRTI Inhibitor Polymerase Active Site NNRTI Binding Pocket Reverse Transcriptase

Inhibition of HIV Reverse Transcription Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) Altered Polymerase Active Site NNRTI Inhibitor Hyperextended thumb region

Reverse Transcriptase Inhibition of HIV Reverse Transcription Nonnucleoside Reverse Transcriptase Inhibitor (NNRTI) E138 Reverse Transcriptase NNRTI Binding Pocket

Resistance to NNRTIs Reverse Transcriptase NNRTI Inhibitor Polymerase Active Site Common Resistance Mutations Reverse Transcriptase

Common NNRTI Resistance Mutations Resistance to Nucleoside Reverse Transcriptase Inhibitors Common NNRTI Resistance Mutations

Case Histories One afternoon in clinic, two patients with virologic failure are seen. Patient 1: 31-year-old man taking tenofovir-emtricitabine- efavirenz (Atripla) and the most recent two HIV RNA levels are 976 and 1,645 copies/ml. A genotype is ordered. Patient 2:26-year-old woman taking tenofovir-emtricitabine- rilpivirine (Complera) and the most recent two HIV RNA levels are 648 and 1,220 copies/ml. A genotype is ordered. What would you expect to find on the genotype for: Patient 1? Patient 2?

2NRTIs + (Efavirenz or Rilpivirine) in ARV-Naive ECHO and THRIVE Pooled Data: Study Design Efavirenz: 600 mg qd + TDF/FTC (n = 344) ECHO Rilpivirine: 25 mg qd + TDF/FTC (n = 346) Efavirenz: 600 mg qd + *2NRTIs (n = 338) THRIVE Rilpivirine: 25 mg qd + *2NRTIs (n = 340) *2 NRTIs: Tenofovir + Emtricitabine; Zidovudine + Lamivudine; Abacavir + Lamivudine Source: Cohen C, et al. J Acquir Immune Defic Syndr. 2012:60:33-42.

2NRTIs + (Efavirenz or Rilpivirine) in ARV-Naive ECHO and THRIVE Pooled Data: Study Design Resistance Findings in ECHO and THRIVE Studies: 48 Week Data Efavirenz (N = 682) Rilpivirine (N = 686) Virologic failure with resistance data, n 28 62 Emergent NNRTI RAMs 54% 63% Most Frequent NNRTI RAMs K103N (73%) E138K (72%) Emergent NRTI RAMs 32% 68% Most Frequent NRTI RAMs M184V (67%) M184I (69%) Source: Cohen C, et al. J Acquir Immune Defic Syndr. 2012;60:33-42.

Virologic Failure with Efavirenz HIV Resistance Genotype Data Study 9341 - K103N > M184V/I + K103N > Other NNRTI mutations ACTG 51422 - K103N > M184V > K65RN > Other NNRTI mutations STARTMRK3 - K103N > M184V 1Study 934: Gallant JE, et al. N Engl J Med. 2006;354:251-60. 2Study 5142. Riddler SA, et al. N Engl J Med. 2008;358;2095-106. 3STARTMRK. Lennox JL, et al. Lancet. 2009;374:796-806.

High-Level Resistance Increased Susceptibility Intermediate Resistance Wild Type HIV-1 Wild Type HIV Efavirenz Etravirine Nevirapine Rilpivirine High-Level Resistance Low-Level Resistance Increased Susceptibility Intermediate Resistance

High-Level Resistance Increased Susceptibility Intermediate Resistance Impact of K103N Mutation K103N Efavirenz Etravirine Nevirapine Rilpivirine High-Level Resistance Low-Level Resistance Increased Susceptibility Intermediate Resistance

High-Level Resistance Increased Susceptibility Intermediate Resistance Impact of E138K Mutation E138K Efavirenz Etravirine Nevirapine Rilpivirine High-Level Resistance Low-Level Resistance Increased Susceptibility Intermediate Resistance

Impact of E138K + M184I Mutation Efavirenz Etravirine Nevirapine Rilpivirine High-Level Resistance Low-Level Resistance Increased Susceptibility Intermediate Resistance

Case History A 46-year-old man is seen in the clinic for evaluation of a salvage antiretroviral regimen. He an has extensive antiretroviral treatment history with multiple episodes of virologic failure. A deep salvage regimen is being considered and the most recent HIV genotype resistance test shows multi-drug class resistance including the following NNRTI-related mutations: - L100I, K101E, K103N, and G190S Do you think any NNRTI medications will likely be effective in a salvage regimen?

Multiple NNRTI Resistance Mutations Mutation Scoring: Stanford HIV Drug Resistance Database RT Efavirenz Etravirine Nevirapine Rilpivirine L100I 45 30 60 K101E 15 K103N G190S Total 180 195 105 Source: Stanford University: HIV Drug Resistance Database (accessed 2/20/2015)

Weighted Scores for Etravirine-Associated Mutations Based on Data from Duet 1 & 2 Individual Mutation Weight to Etravirine 1.0 1.5 2.5 3 V90I A98G K101E K101H V179D V179T G190A V106I E138A V179F G190S L100I K101P Y181C M230L Y181I Y181V Source: Vingerhoets J, et al. AIDS. 2010;24:503-14.

Weighted Scores for Etravirine-Associated Mutations Based on Data from Duet 1 & 2 Individual Mutation Weight to Etravirine 1.0 1.5 2.5 3 V90I A98G K101E K101H V179D V179T G190A V106I E138A V179F G190S L100I K101P Y181C M230L Y181I Y181V L100I (2.5), K101E (1.0), K103N (0), and G190S (1.5) = Weighted Score of 5 Source: Vingerhoets J, et al. AIDS. 2010;24:503-14.

Weighted Scores for Etravirine-Associated Mutations Based on Data from Duet 1 & 2 Duet-1 and Duet-2: Etravirine Susceptibility Score and Virologic Response at Week 24 Highest Response Intermediate Response Reduced Response Source: Vingerhoets J, et al. AIDS. 2010;24:503-14.